Therefore, targeting the mTOR pathway in the CNS through IN delivery could be a way to reduce the detrimental effects not only due to Down syndrome and stroke, but also other neurological diseases that have increased mTOR activity. The gene discussed is MTOR; the disease is Down syndrome.